DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Phase 1

Recruiting

Conditions: Carcinoma, Neuroendocrine
Carcinoma, Adrenal Cortical
Neuroendocrine Tumors
Neuroendocrine Carcinomas
Carcinoma, Adrenocortical

Interventions: Drug: ADCT-701

First Posted Date: 2023-09-18

Last Posted Date: 2025-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT06041516

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Phase 2

Not yet recruiting

Conditions: Squamous Cell Carcinoma of the Bladder
Testicular Germ Cell Tumors
Adenocarcinoma of the Bladder

Interventions: Drug: Pembrolizumab
Drug: Enfortumab vedotin

First Posted Date: 2023-09-18

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT06041503

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2

Recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions: Procedure: Bone Scan
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Carboplatin
Procedure: Magnetic Resonance Imaging
Drug: Cisplatin
Procedure: Positron Emission Tomography
Drug: Gemcitabine
Biological: Relatlimab
Biological: Nivolumab

First Posted Date: 2023-09-08

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT06029270

Locations: 🇺🇸
Bozeman Health Deaconess Hospital, Bozeman, Montana, United States
🇺🇸
Benefis Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States

and more 92 locations

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Dietary Supplement: Urolithin A Supplement
Drug: Placebo Administration

First Posted Date: 2023-09-05

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT06022822

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 2 locations

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lenalidomide
Biological: Mosunetuzumab
Drug: Polatuzumab Vedotin
Procedure: Positron Emission Tomography

First Posted Date: 2023-08-29

Last Posted Date: 2025-03-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT06015880

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 5 locations

Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters

Phase 2

Suspended

Conditions: Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Dietary Supplement: Broccoli Sprout/Broccoli Seed Extract Supplement
Drug: Placebo Administration
Other: Questionnaire Administration
Other: Training

First Posted Date: 2023-08-24

Last Posted Date: 2025-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT06009926

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States

Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)

Recruiting

Conditions: Lipodystrophy

First Posted Date: 2023-08-18

Last Posted Date: 2025-03-19

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 14

Registration Number: NCT05996536

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Phase 2

Recruiting

Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)

Interventions: Biological: PRGN-2009
Drug: Pembrolizumab

First Posted Date: 2023-08-18

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT05996523

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Phase 1

Recruiting

Conditions: Human Papillomavirus-Related Carcinoma

Interventions: Procedure: Biospecimen Collection
Biological: HPV16 RG1 VLP Vaccine
Other: Questionnaire Administration
Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Other: Saline

First Posted Date: 2023-08-14

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT05985681

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Staten Island University Hospital, Staten Island, New York, United States

and more 2 locations

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Phase 2

Recruiting

Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Muscle Invasive Bladder Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: cfDNA or ctDNA Measurement
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Relatlimab

First Posted Date: 2023-08-14

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1190

Registration Number: NCT05987241

Locations: 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 388 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy